Alessandro Bonardi Selected Research

Neoplasms (Cancer)

3/2024	Sulfonamide-incorporated bis(α-aminophosphonates) as promising carbonic anhydrase inhibitors: Design, synthesis, biological evaluation, and X-ray crystallographic studies.
2/2024	Synthetic Approaches to Novel Human Carbonic Anhydrase Isoform Inhibitors Based on Pyrrol-2-one Moiety.
1/2024	Exploring the potency of diazo-coumarin containing hybrid molecules: Selective inhibition of tumor-associated carbonic anhydrase isoforms IX and XII.
12/2023	Selenium-analogs based on natural sources as cancer-associated carbonic anhydrase isoforms IX and XII inhibitors.
12/2023	Effect of hydrophobic extension of aryl enaminones and pyrazole-linked compounds combined with sulphonamide, sulfaguanidine, or carboxylic acid functionalities on carbonic anhydrase inhibitory potency and selectivity.
10/2023	Design and synthesis of sulfonamides incorporating a biotin moiety: Carbonic anhydrase inhibitory effects, antiproliferative activity and molecular modeling studies.
10/2023	6-Aminocoumarin oxime-ether/sulfonamides as selective hCA IX and XII inhibitors: Synthesis, evaluation, and molecular dynamics studies.
8/2023	Inhibition Profiles of Some Novel Sulfonamide-Incorporated α-Aminophosphonates on Human Carbonic Anhydrases.
6/2023	Discovery of Novel Hydroxyimine-Tethered Benzenesulfonamides as Potential Human Carbonic Anhydrase IX/XII Inhibitors.
1/2023	6-Substituted Triazolyl Benzoxaboroles as Selective Carbonic Anhydrase Inhibitors: In Silico Design, Synthesis, and X-ray Crystallography.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Bonardi Research Topics

Disease

26	Neoplasms (Cancer) 03/2024 - 02/2018
5	Glaucoma 01/2022 - 10/2019
3	Neuralgia (Stump Neuralgia) 10/2023 - 01/2021
2	Neoplasm Metastasis (Metastasis) 10/2023 - 02/2018
2	Chagas Disease (American Trypanosomiasis) 12/2022 - 04/2019
1	Type 2 Diabetes Mellitus (MODY) 04/2024
1	Diabetes Mellitus 04/2024
1	Mitochondrial Diseases (Mitochondrial Disease) 03/2024
1	Amyloid Plaque 03/2024
1	Alzheimer Disease (Alzheimer's Disease) 03/2024
1	Tuberculosis (Tuberculoses) 02/2024
1	Hypoxia (Hypoxemia) 10/2023
1	Pain (Aches) 10/2022
1	Arthritis (Polyarthritis) 10/2022
1	Epilepsy (Aura) 01/2022
1	Altitude Sickness (Mountain Sickness) 01/2022
1	Edema (Dropsy) 01/2022
1	Colitis 01/2021
1	Visceral Pain 01/2021
1	Breast Neoplasms (Breast Cancer) 03/2020
1	Ocular Hypertension (Glaucoma, Suspect) 10/2019
1	Kidney Neoplasms (Kidney Cancer) 05/2019
1	Leishmaniasis 04/2019
1	Colonic Neoplasms (Colon Cancer) 02/2018

Drug/Important Bio-Agent (IBA)

20	Protein Isoforms (Isoforms)IBA 03/2024 - 02/2018
19	Carbonic Anhydrases (Carbonic Anhydrase)IBA 03/2024 - 02/2018
7	SulfonamidesIBA 10/2023 - 12/2019
5	BenzenesulfonamidesIBA 04/2024 - 05/2018
3	EnzymesIBA 04/2024 - 11/2020
3	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2024 - 01/2023
3	SLC-0111IBA 10/2023 - 12/2022
3	Carbonic Anhydrase InhibitorsIBA 01/2023 - 04/2019
2	LigandsIBA 04/2024 - 03/2024
2	coumarinIBA 01/2024 - 03/2020
2	CoumarinsIBA 11/2020 - 02/2018
1	Carbonic Anhydrase IIIBA 04/2024
1	GlucosidasesIBA 04/2024
1	Organophosphonates (Phosphonates)IBA 03/2024
1	Methazolamide FDA LinkGeneric 03/2024
1	Monoamine Oxidase (MAO)IBA 03/2024
1	Peptides (Polypeptides)IBA 03/2024
1	Cholinergic Agents (Cholinergics)IBA 03/2024
1	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2024
1	Amyloid (Amyloid Fibrils)IBA 03/2024
1	Rifampin (Rifampicin)FDA LinkGeneric 02/2024
1	Isoniazid (Ftivazide)FDA LinkGeneric 02/2024
1	Propidium (Propidium Iodide)IBA 12/2023
1	Cytotoxins (Cytolysins)IBA 12/2023
1	Organoselenium CompoundsIBA 12/2023
1	FITC-annexin A5IBA 12/2023
1	SeleniumIBA 12/2023
1	IsoenzymesIBA 10/2023
1	Biotin (Vitamin H)FDA Link 10/2023
1	cathepsin SIBA 10/2023
1	compound 30IBA 06/2023
1	ZincIBA 06/2023
1	Antineoplastic Agents (Antineoplastics)IBA 01/2023
1	benzothiazoleIBA 12/2022
1	Antiprotozoal AgentsIBA 12/2022
1	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 10/2022
1	3- (5- nitrofuryl)- 7- (5- nitrofurfurylidene)- 3,3a,4,5,6,7- hexahydro- 2H- indazoleIBA 10/2022
1	pyrazoleIBA 01/2022
1	KetonesIBA 01/2022
1	Sulfanilamide FDA Link 01/2022
1	piperineIBA 12/2021
1	2,4-dinitrofluorobenzene sulfonic acidIBA 01/2021
1	Sulfonic AcidsIBA 01/2021
1	Carbonic Anhydrase IVIBA 01/2021
1	FuraginIBA 12/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2020
1	pyrimidineIBA 03/2020
1	Fluorouracil (Carac)FDA LinkGeneric 03/2020
1	Carbonic Anhydrase IXIBA 03/2020
1	dorzolamide (Trusopt)FDA LinkGeneric 01/2020
1	isoquinolineIBA 10/2019
1	AmidesIBA 10/2019
1	Adrenergic Agents (Adrenergic Drugs)IBA 10/2019
1	Adrenergic Antagonists (Antiadrenergic Agents)IBA 10/2019
1	ProstaglandinsIBA 10/2019
1	benzamideIBA 10/2019
1	rho-Associated KinasesIBA 10/2019
1	Muscarinic AgonistsIBA 10/2019
1	K-115IBA 10/2019
1	DiamideIBA 05/2019
1	SaltsIBA 04/2019
1	SteroidsIBA 12/2018

Therapy/Procedure

2	Therapeutics 01/2021 - 02/2018